Engflag

Iodantipirin

Quick links to important sections

Iodantipirin

Selected form

Iodantipirin_EN

Method of action: Anti-Inflammatory, Immunomodulating

Treatment option: Influenza, Parainfluenza, Stomatitis, Encephalitis

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Iodantipirin

Iodantipirin is a synthetic pharmaceutical preparation categorized as both an Antiviral Agent and a Non-Steroidal Anti-Inflammatory Drug (NSAID), primarily used to support the body in tackling viral challenges. It is a single-ingredient medication supplied in the standard oral dosage form of tablets. This medication is clinically recognized for its unique dual function, offering both support against viral proliferation and relief from inflammatory symptoms.

Property Description
Active ingredient Iodoantipyrine (Iodophenazone)
Form Tablets (Oral dosage form)
Pharmacological class Antiviral Agent and NSAID
General purpose Supports immune response against viruses and addresses inflammation
Origin Synthetic (Pyrazolone derivative)

Iodantipirin: Definition, Active Ingredient, and Drug Form

The active ingredient in this medication is Iodophenazone, which is also known by the International Nonproprietary Name (INN) Iodoantipyrine (4-Iodoantipyrine). It is a synthetic compound structurally related to the original analgesic, antipyrine (phenazone), but includes an iodine atom, making it an iodinated pyrazolone derivative. This specific chemical alteration differentiates Iodophenazone from its parent compound, establishing its distinct role in therapy. It is generally prepared for oral administration as a solid tablet.

What Pharmacological Class Does Iodantipirin Belong To?

Iodantipirin belongs to two critical pharmacological classes: it is an Antiviral Agent and simultaneously holds properties of a Non-Steroidal Anti-Inflammatory Drug (NSAID). Its unique mechanism involves functioning as an interferon inducer, a classification indicating that it actively encourages the body's natural release of its own innate antiviral proteins. This immunomodulatory action is crucial to its classification and therapeutic profile.

General Purpose: Why is Iodantipirin Used?

The general purpose of using Iodantipirin is to provide the body with a robust mechanism for intervening against viral challenges while concurrently managing the associated inflammatory response. The principle of using interferon inducers is well-established in the context of viral infections. By promoting the release of interferons and exerting an anti-inflammatory effect, the drug provides a dual mechanism intended to mitigate systemic discomfort often accompanying a viral illness.

What side effects are possible with Iodantipirin?

Possible Side Effects and Safety Information

The safety profile for Iodantipirin is strictly defined and monitored by official government regulatory authorities, such as the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), through mandated pre- and post-marketing data collection.

Adverse reactions—also known as side effects—are documented and categorized based on their frequency and the body system affected (System-Organ Class or SOC). This structured classification helps to formally present the known risks associated with the medicine.

Official Adverse Reaction Classification

Official regulatory texts classify reported side effects using standardized frequency categories (e.g., Common, Uncommon, Rare, Very Rare, Not Known). This categorization is essential for communicating the likelihood of an event occurring based on collected safety data. These reports are often grouped by the body system involved (e.g., Nervous System Disorders, Skin and Subcutaneous Tissue Disorders).

Regulatory Safety Monitoring and Limitations

All medicines are subject to continuous Post-Authorization Safety Monitoring, where regulatory agencies systematically collect and evaluate reports of suspected adverse reactions, including those resulting from medication errors, overdose, or misuse. Serious adverse reactions are defined and subject to expedited reporting to ensure timely safety profile updates.

Regulatory documents also define specific Restrictions and Limitations for the medicine's use. These may include official contraindications, warnings, and precautions that restrict use in certain patient populations (e.g., those with specific underlying conditions) due to documented safety risks. The regulatory framework ensures the safety information remains current throughout the product’s lifecycle.

Overdose and Emergency Response

Suspected overdose with Iodantipirin, an iodinated pyrazolone derivative, necessitates immediate medical attention due to the potential for severe, life-threatening outcomes. The documented clinical manifestations typically affect multiple physiological systems, and are officially required to be reported immediately to emergency services.

System Affected Documented Clinical Manifestations Severe/Life-Threatening Outcomes
Gastrointestinal Severe abdominal pain, vomiting, diarrhea (may be bloody), salivation, and a metallic taste in the mouth. Esophageal stricture (long-term risk)
Neurological Fever, delirium, and a decreased level of alertness (stupor) alongside general systemic discomfort. Seizures and systemic shock
Systemic/Renal Rash, coughing, mouth and throat pain/burning. Acute renal failure (no urine output)

Mandatory Emergency Actions Individuals must seek immediate medical help if an overdose is suspected, providing details on the amount taken and the time of ingestion. Due to the risk of systemic collapse, including shock, continuous monitoring of the patient's vital signs and mental status is required at a medical facility. Treatment procedures are officially defined as supportive and symptomatic, focusing on stabilizing the patient’s airway, breathing, and circulation. Supportive interventions listed in regulatory documents may include the administration of activated charcoal and intravenous fluids. It is noted that there is no specific antidote known for this poisoning. The official profile also identifies specific populations—older patients, those with preexisting thyroid disease, neonates, and fetuses—as being at an increased risk of delayed thyroid dysfunction from iodine exposure.

Therapeutic Uses of Iodantipirin

Iodantipirin is primarily classified as an antiviral agent with distinct pharmacological properties that are relevant for addressing inflammatory or irritative states. This combination of properties generally supports the patient during symptomatic phases, which contributes to easing the overall symptom load and helps improve day-to-day comfort.

The medication is commonly used across conditions presenting with acute episodes and often applied in clinical settings that involve acute or unstable symptom patterns. It is utilized for the prophylaxis and treatment of tick-borne encephalitis (TBE) in adults and is considered relevant in clinical contexts involving heightened systemic burden following potential exposure. It is also applied in the complex treatment of Hemorrhagic Fever with Renal Syndrome (HFRS). The drug is relevant for easing symptoms related to systemic imbalance and symptoms associated with acute or episodic changes. The medication may assist with maintaining functional stability and offers symptomatic relief that helps patients cope more steadily with symptom fluctuations, particularly those symptoms related to heightened physiological activity.

Quick Fact: Relief for Symptoms related to heightened physiological activity.

Eligibility and Restrictions for Use

Who Can and Cannot Use Iodantipirin: Official Regulatory Information

The official regulatory profile for Iodantipirin (Iodophenazone) defines the eligible population based on specific contraindications stated in authorized labeling by national health authorities. These restrictions strictly outline who may and who must not use the medicine.

Eligibility Scope

Classification Population or Condition
Populations Allowed Adults and adolescents 14 years of age and older
Absolute Contraindication Hypersensitivity to Iodophenazone or other iodine-containing preparations
Absolute Contraindication Children under 14 years of age

Condition-Based and Physiological Restrictions

Use of Iodantipirin is absolutely contraindicated in patients with certain pre-existing conditions or physiological states:

  • Endocrine Status: Contraindicated in patients with Hyperfunction of the thyroid gland (Hyperthyroidism).
  • Organ Function: Contraindicated in cases of Severe impairment of liver function (Severe Hepatic Insufficiency).
  • Organ Function: Contraindicated in cases of Severe impairment of kidney function (Severe Renal Insufficiency).
  • Physiological State: Contraindicated during pregnancy and during the lactation period (breastfeeding).

Regulatory Connection: These official statements define a non-eligible population, ensuring the medicine is strictly reserved for individuals 14 years or older who do not present with the specified organ or endocrine pathology, or women who are not pregnant or breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents detail specific drug-drug interaction concerns for Iodantipirin, primarily focusing on medicinal products that affect blood clotting. These statements establish constraints for co-administration to maintain patient safety and therapeutic consistency.

Documented Interaction Domains

Interacting Product Category Specific Examples Cited Regulatory Constraint/Requirement
Anticoagulants Warfarin Requires close monitoring of blood coagulation parameters
Antiplatelet Agents N/A Risk of increased anti-clotting effect

Co-administration with anticoagulants, particularly Warfarin, presents the key interaction concern noted in official product labeling. The concurrent use of these medicines carries a documented risk of an enhanced anticoagulant effect, which may lead to excessive blood thinning. Due to this potential for altered therapeutic outcomes, regulatory bodies require that patients receiving both Iodantipirin and Warfarin undergo rigorous and consistent monitoring of their blood coagulation parameters.

While specific examples are limited, the overall interaction profile highlights the need for careful medical supervision when Iodantipirin is introduced or discontinued in the context of any ongoing therapy that influences hemostasis or blood clotting.

Mechanism of Action

Iodantipirin's mechanism of action is primarily mediated by the inhibition of cyclooxygenase (COX) enzyme activity, leading to a decrease in the biosynthesis of prostaglandins. The antipyrine moiety of the compound functions as an inhibitor, interacting with the active site of the COX enzyme to modulate the conversion of arachidonic acid into pro-inflammatory mediators, chiefly prostaglandin E2 (PGE2). This reduced PGE2 synthesis constitutes the core mechanistic cascade of the drug.

The iodine component is implicated in the modulation of localized biochemical signaling, which may influence downstream inflammatory pathways such as NF-kappa B activation. Furthermore, a component within Iodantipirin's metabolite profile exhibits free radical scavenging activity. This scavenging capacity modulates the integrity of cellular membranes in contexts of oxidative stress, contributing to the system-level physiological modulation of cellular processes. The combined effect centers on modifying the signaling output of eicosanoid and redox pathways.

Dosage and Administration Information

Iodantipirin is a medication that is administered orally as a 100 mg tablet. All official administration schedules are specifically designed for adults and are determined by the intended use scenario. A core requirement for proper use is that the tablets must be taken after meals (post cibum).

Usage patterns generally fall into structured, short-term treatment courses or continuous, fixed-dose prophylaxis. The total dose and frequency are dictated by the purpose of use.

Use Scenario Duration Dosing Pattern (Adults)
TBE Treatment / Post-Exposure 10 days Begins with 300 mg three times daily (TID) for two days, followed by a tapering schedule that reduces the dose over the subsequent eight days.
HFRS Treatment 9 days Begins with 200 mg TID for four days, reducing to 100 mg TID for the remaining five days.
Seasonal TBE Prophylaxis Full Exposure Period 200 mg once daily (QD), sustained for the entire duration of potential exposure.

The most common regimens follow a structured, total dose reduction over several days. The course for post-exposure management of TBE, for example, involves two days at the highest dose (300 mg TID) followed by subsequent, mandated dose reductions. A specific procedural constraint notes that the medication is not to be used at the same time as anti-tick immunoglobulin.

Recent Clinical Evidence

Research evidence / Overview of Studies for Iodantipirin

Evidence for use in Tick-Borne Encephalitis (TBE)

Research has explored the medicine's use in studies of the prophylaxis (prevention) and treatment of Tick-Borne Encephalitis (TBE). This research was studied for its potential role in addressing the condition, which is associated with acute or disruptive episodes. In the laboratory and animal models, research examined measurements of survival rate following exposure to the TBE virus. Studies also monitored the compound's biological activity, specifically its known capacity as an interferon inducer.

Findings from preclinical research described patterns observed in the survival of infected animals during the study period. Additionally, evidence shows patterns related to the compound's influence on the body's natural release of antiviral proteins. The available data included the medicine's authorized indication for the treatment and prevention of TBE in adult patients.

Evidence for use in Hemorrhagic Fever with Renal Syndrome (HFRS)

Iodantipirin was evaluated in clinical settings for the medicine's role within the complex treatment of Hemorrhagic Fever with Renal Syndrome (HFRS), a condition characterized by fluctuating or episodic manifestations. Research examined what outcomes were monitored related to daily functioning during the acute phase of the illness. Studies monitored patient-reported outcomes describing perceived discomfort linked to inflammatory or irritative states.

Research evaluated the medicine's role within a multi-component therapeutic approach for HFRS. Studies monitored how symptoms changed in the observed adult populations. Findings describe patterns observed in the research related to managing systemic discomfort and supporting functional stability, particularly during periods of increased symptom activity.

What is Still Uncertain About Iodantipirin's Research

Comparative evidence against other treatments is currently lacking in published literature. Evidence for HFRS is limited because the specific study designs, including comparators and detailed endpoints from the clinical trials used for registration, are not broadly published in international scientific databases. The research so far indicates that the evidence quality varies across studies. The findings provide context but not individual predictions, and research does not determine whether an individual will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Iodantipirin (FAQ)

Q: Is it possible for Iodantipirin to cause a skin rash?

Official regulatory documents classify potential health issues by the body system affected. These classifications include Skin and Subcutaneous Tissue Disorders. This indicates that skin-related reactions are a type of side effect included within this officially categorized group, but specific frequency details are in the full product information.

Q: Why is blood monitoring sometimes suggested for people taking Iodantipirin?

Blood monitoring is specifically mentioned in regulatory information when Iodantipirin is used at the same time as certain other medicines, particularly anticoagulants like Warfarin. Official product information notes a risk of an enhanced anticoagulant effect, which may lead to excessive blood thinning. Close monitoring of blood clotting tests is required under regulatory guidance in this specific circumstance.

Q: What happens if you miss a dose of Iodantipirin?

Official patient information leaflets typically address how to handle a dose that has been forgotten. Generally, the instruction advises against taking a double dose to compensate for a missed one. Guidance on a specific course of action is detailed in the patient information supplied with the medicine.

Q: Is it normal to feel a bit drowsy after taking Iodantipirin?

Adverse effects related to the nervous system, such as drowsiness (somnolence), would be officially listed in the Adverse Reactions section of the product information if reported. These effects are formally categorized under Nervous System Disorders. The documented likelihood of this side effect is outlined in the full official labeling.

Q: What is the shelf life of Iodantipirin tablets?

According to official regulatory documents, the authorized shelf-life for the Iodantipirin tablets is 3 years from the date of manufacture. It is important to adhere to the expiration date listed on the packaging.

Q: Can children take Iodantipirin, and if so, what are the guidelines?

Iodantipirin is approved for use only in adults and adolescents 14 years of age and older. Official guidance states that use is absolutely contraindicated in children under 14 years of age.

Q: What should I do if I think I'm experiencing a severe side effect from Iodantipirin?

All medicines are subject to continuous Post-Authorization Safety Monitoring, which requires systematic reporting of suspected adverse reactions to regulatory agencies. Official protocols require systematic reporting of suspected serious adverse reactions to regulatory agencies. Concerns regarding any severe reaction should be addressed promptly with a healthcare professional.

Q: Does Iodantipirin have a sedative effect?

Sedative effects are typically categorized under Central Nervous System (CNS) effects in the official Adverse Reactions listings. Whether Iodantipirin has a sedative effect, and how frequently, is detailed in the full official safety labeling provided by regulatory authorities.

How should Iodantipirin be stored and disposed of?

Official Storage and Disposal Requirements

Iodantipirin tablets must be stored strictly according to the conditions defined in the official regulatory documentation to maintain stability for the authorized 3-year shelf-life.

Storage Conditions

The required storage environment has a temperature limit that must not exceed 25°C. The medicine must also be kept in a dry place and a place protected from light.

Regulatory requirements mandate that the product must always be stored out of the sight and reach of children to ensure safety.

Disposal

Official labeling does not provide specific instructions for household disposal. Any unused or expired Iodantipirin must be disposed of according to local and national pharmaceutical waste handling requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagRussia

Equivalent of Iodantipirin found in:

A-Z Index: